Charles River Laboratories International (NYSE:CRL) PT Lowered to $239.00

Charles River Laboratories International (NYSE:CRL) had its price objective decreased by Robert W. Baird from $271.00 to $239.00 in a research report sent to investors on Wednesday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

CRL has been the subject of several other research reports. Barclays initiated coverage on shares of Charles River Laboratories International in a research report on Friday, June 28th. They set an equal weight rating and a $230.00 price target for the company. Mizuho initiated coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They issued a neutral rating and a $235.00 target price for the company. Argus reaffirmed a hold rating on shares of Charles River Laboratories International in a research report on Friday, June 28th. The Goldman Sachs Group initiated coverage on shares of Charles River Laboratories International in a research report on Thursday, June 6th. They issued a buy rating and a $290.00 target price for the company. Finally, TD Cowen cut their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating for the company in a research report on Monday, May 13th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of Hold and an average price target of $252.29.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $202.71 on Wednesday. The company has a market capitalization of $10.44 billion, a price-to-earnings ratio of 23.85, a P/E/G ratio of 1.92 and a beta of 1.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. The company has a 50 day simple moving average of $215.19 and a two-hundred day simple moving average of $231.01. Charles River Laboratories International has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. Analysts expect that Charles River Laboratories International will post 11 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 1.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRL. Deutsche Bank AG boosted its holdings in shares of Charles River Laboratories International by 6.9% during the 3rd quarter. Deutsche Bank AG now owns 123,119 shares of the medical research company’s stock valued at $24,129,000 after purchasing an additional 7,944 shares during the last quarter. Neo Ivy Capital Management bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at about $216,000. VisionPoint Advisory Group LLC raised its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 5,953,860 shares of the medical research company’s stock valued at $1,166,837,000 after buying an additional 29,482 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its position in shares of Charles River Laboratories International by 21.5% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock valued at $78,000 after buying an additional 58 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).